Stocks TelegraphStocks Telegraph
Stock Ideas

PRLD Financial Statements and Analysis

NASDAQ : PRLD

Prelude Therapeutics

$4.60
-0.45-8.91%
At Close 4:00 PM
65.46
B-ESG ScoreESG Rating

FINANCIAL STATEMENTS

An instrumental part of fundamental analysis is measuring key indicators of an asset, which are the factors that can influence its value and price. However, sometimes investors show more interest in financial statements with other factors to determine whether investing in that company is the right decision. Financial statements of a company include:

  • Balance Sheet
  • Income Statement
  • Cash Flow Statement

Income Statement

A company's income statement helps investors and business owners determine whether the company is profitable or losing money. Profitability is a key factor investors consider before investing in a stock. Income statements provide them with information about a company's profitability over time. The statement also enables them to observe trends in company spending and earnings since it breaks down individual costs and revenues. Income statements also provide details on where a company's money is going when it isn't profitable or its profits fluctuate.

DateMar 31, 2026Sep 30, 2025Jun 30, 2025Mar 31, 2025Sep 30, 2024
reported currencyUSDUSDUSDUSDUSD
calendar year20262025202520252024
periodQ1Q3Q2Q1Q3
revenue4.58M6.50M003.00M
cost of revenue391.00K425.00K000
gross profit4.189M6.075M003.00M
gross profit ratio0.9150.935001.00
research and development expenses13.601M21.708M25.784M28.816M29.457M
general and administrative expenses5.156M06.41M5.79M7.919M
selling and marketing expenses-391.00K0000
selling general and administrative expenses4.765M4.785M6.41M5.79M7.919M
other expenses00000
operating expenses18.366M26.493M32.194M34.606M37.376M
cost and expenses18.757M26.918M32.194M34.606M37.376M
interest income00000
interest expense00000
depreciation and amortization391.00K425.00K433.00K435.00K405.00K
ebitda-9.994M-19.30M-31.761M-34.171M-33.971M
ebitda ratio-2.182-2.96900-11.324
operating income-14.177M-20.418M-32.194M-34.606M-34.376M
operating income ratio-3.095-3.14100-11.459
total other income expenses net3.792M693.00K963.00K2.521M2.105M
income before tax-10.385M-19.725M-31.231M-32.085M-32.271M
income before tax ratio-2.267-3.03500-10.757
income tax expense00000
net income-10.385M-19.725M-31.231M-32.085M-32.271M
net income ratio-2.267-3.03500-10.757
eps-0.13-0.26-0.41-0.42-0.43
eps diluted-0.13-0.26-0.41-0.42-0.43
weighted average shs out82.52M76.132M75.994M75.986M75.856M
weighted average shs out dil82.52M76.132M75.994M75.986M75.856M
Graph

Balance Sheet

Balance sheet summarizes a company's financials and can be used as a basis by investors to determine the value of a company. It shows the value of the stock, as well as the assets and liabilities of the company. A company's balance sheet displays how its assets are put to use and how those assets are financed, based on the liabilities section. Both investors and analysts analyze a company's balance sheet to determine how it allocates its resources.

DateMar 31, 2026Sep 30, 2025Jun 30, 2025Mar 31, 2025Sep 30, 2024
reported currencyUSDUSDUSDUSDUSD
calendar year20262025202520252024
periodQ1Q3Q2Q1Q3
cash and cash equivalents21.756M47.532M25.752M40.269M11.134M
short term investments59.798M7.425M47.464M58.805M142.492M
cash and short term investments81.554M54.957M73.216M99.074M153.626M
net receivables00000
inventory00000
other current assets3.039M3.373M3.66M3.329M2.761M
total current assets84.593M58.33M76.876M102.403M156.387M
property plant equipment net31.50M33.08M33.888M34.703M36.384M
goodwill00000
intangible assets00000
goodwill and intangible assets00000
long term investments03.235M000
tax assets00000
other non current assets3.549M110.00K4.154M4.154M4.449M
total non current assets35.049M36.425M38.042M38.857M40.833M
other assets00000
total assets119.642M94.755M114.918M141.26M197.22M
account payables2.069M2.533M4.962M5.831M5.921M
short term debt2.761M2.727M2.711M2.653M2.724M
tax payables00000
deferred revenue30.952M0000
other current liabilities5.938M12.93M13.235M11.303M13.579M
total current liabilities41.72M18.19M20.908M19.787M22.224M
long term debt14.96M15.127M15.206M15.267M15.412M
deferred revenue non current00000
deferred tax liabilities non current00000
other non current liabilities2.779M2.904M2.966M3.028M3.153M
total non current liabilities17.739M18.031M18.172M18.295M18.565M
other liabilities00000
capital lease obligations17.721M017.917M17.92M18.136M
total liabilities59.459M36.221M39.08M38.082M40.789M
preferred stock00000
common stock6.00K5.00K5.00K5.00K4.00K
retained earnings-693.446M-666.604M-646.879M-615.648M-554.832M
accumulated other comprehensive income loss-41.00K2.00K-1.00K12.00K167.00K
other total stockholders equity753.664M725.131M722.713M718.809M711.092M
total stockholders equity60.183M58.534M75.838M103.178M156.431M
total equity60.183M58.534M75.838M103.178M156.431M
total liabilities and stockholders equity119.642M94.755M114.918M141.26M197.22M
minority interest00000
total investments59.798M10.66M47.464M58.805M142.492M
total debt17.721M17.854M17.917M17.92M18.136M
net debt-4.035M-29.678M-7.835M-22.349M7.002M
Graph

Cash Flow

A cash flow statement is regarded as a valuable indicator of profitability and the long-term outlook for a company. It assists the company in evaluating whether it has sufficient funds to cover its expenses. Essentially, a cash flow statement represents an organization's financial health. The cash flow statement, which measures the business's ability to operate in the short as well as long term, is broken down into operating, investing, and financing activities.

DateMar 31, 2026Sep 30, 2025Jun 30, 2025Mar 31, 2025Sep 30, 2024
reported currencyUSDUSDUSDUSDUSD
calendar year20262025202520252024
periodQ1Q3Q2Q1Q3
deferred income tax00000
stock based compensation2.00M03.814M3.832M12.018M
change in working capital-13.69M-2.572M739.00K-6.876M-862.00K
accounts receivables00000
inventory00000
accounts payables-1.879M-2.429M-850.00K-1.91M-213.00K
other working capital-11.811M-143.00K1.589M-4.966M846.00K
other non cash items-1.00K2.757M170.00K463.00K-2.898M
net cash provided by operating activities-21.685M-19.115M-26.075M-34.231M-27.296M
investments in property plant and equipment00-20.00K-47.00K-63.00K
acquisitions net00000
purchases of investments00-24.664M-9.463M-31.994M
sales maturities of investments8.499M40.091M36.205M71.696M42.79M
other investing activites00000
net cash used for investing activites8.499M40.091M11.521M62.186M10.733M
debt repayment00-53.00K-155.00K-244.00K
common stock issued-263.00K092.00K080.00K
common stock repurchased000-5.00K34.00
dividends paid00000
other financing activites-51.00K-5.00K-2.00K032.966K
net cash used provided by financing activities-314.00K-5.00K37.00K-160.00K-131.00K
effect of forex changes on cash0809.00K000
net change in cash-13.50M21.78M-14.517M27.795M-12.65M
cash at end of period21.756M47.532M29.796M44.313M15.178M
cash at beginning of period35.256M25.752M44.313M16.518M27.828M
operating cashflow-21.685M-19.115M-26.075M-34.231M-27.296M
capital expenditure00-20.00K-47.00K-63.00K
free cash flow-21.685M-19.115M-26.095M-34.278M-27.359M
Graph

Frequently Asked Questions

How did Prelude Therapeutics Incorporated do last quarter? What was its Total Revenue and Cost of Revenue?
A company's Total Revenue reveals how much money it generates before any expenses or deductions are made. As a result, this metric informs investors/stakeholders how much money the business makes. Tracking and understanding it is essential for evaluating a company's growth. As opposed to revenue, Cost of Revenue is any expenses a business incur to generate revenue. There can be high revenue in a business, but if the costs are high, it won't make a profit and will go out of business when money runs out. Therefore, PRLD generated $4.58M in revenue last quarter, while its costs came in at $391.00K.
Last quarter, how much Gross Profit did Prelude Therapeutics Incorporated report?
A business's Gross Profit is a key indicator of its profitability and financial performance. In other words, it reflects how efficiently a business uses labor, raw materials, and other resources. Prelude Therapeutics Incorporated reported a $4.19M Gross Profit for the quarter ended Mar 31, 2026.
Have PRLD's Total Operating Expenses and Operating Income been favorable recently?
Operational Expenses represent the costs a company must incur to generate revenue, which is the ultimate goal of a business, whereas Operating Income shows the revenue left after operational direct and indirect costs have been deducted. PRLD incurred $18.37M worth of Operating Expenses, while it generated -$14.18M worth of Operating Income.
How much Net Income has PRLD posted recently?
The Net Income of a company is one of the factors investors consider when investing in the company. According to recent earnings report from Prelude Therapeutics Incorporated, the company generated -$10.39M in Net Income. When a company has a history of consistent net income, investors are more likely to invest in it since they know they will get a return.
At the end of the last quarter, how much Cash and Equivalents did Prelude Therapeutics Incorporated have?
The amount of Cash and Cash Equivalents is an effective indicator of the financial strength and well-being of a company. An excess cash situation occurs when a company has more cash and cash equivalents than it needs for operating activities. The amount of Cash and Cash Equivalents available to Prelude Therapeutics Incorporated as of the end of the last quarter was $21.76M.
What are PRLD's Total Net Receivables for the last quarter?
Total Net Receivables are a company's outstanding debts to its customers. Therefore, it refers to the amount that a company expects to collect from its customers. The higher a company's net receivables are, the more confident it is that it can collect money from its debtors. As of the end of the last quarter, PRLD had Total Net Receivables of $0.00.
In terms of Total Assets and Current Assets, where did Prelude Therapeutics Incorporated stand at?
An asset with an economic value within a year is considered a current asset. Total assets, however, also include long-term fixed assets, intangible assets, and other non-current assets. The current Assets of PRLD were $84.59M, while the Total Assets stand at $119.64M.
As of the last quarter, how much Total Debt did Prelude Therapeutics Incorporated have?
The total debt of a business refers to how much it borrows. A company's current and long-term liabilities are added together to calculate its Total Debt. A debt ratio may be taken into account on a balance sheet by financial lenders, investors, and business leaders when making informed decisions about future loans or investments. The total amount of PRLD's debt was $17.72M at the end of the last quarter.
What were PRLD's Total Liabilities during the last reported quarter?
A company's total liabilities are the sum of all debts it is liable for, including any off-balance shee liabilities it may incur. This can be calculated by adding up all short-term and long-term liabilities. In its last quarter, PRLD reported total liabilities of $59.46M.
How much did PRLD's Working Capital change over the last quarter?
Working Capital Change for PRLD was -$13.69M over the last quarter. Working Capital Change refers to the difference between net working capital amounts at the end of one accounting period and the end of another. It tells investors/stakeholders how much the company's cash flow will differ from its Net Income (i.e., after-tax profits). More powerful companies often have positive Change in Working Capital numbers as they have increased control over collecting cash from customers and delaying payments to suppliers.
PRLD generated how much cash from operating activities?
An operating cash flow statement usually contains cash from operating activities in the first section. An organization's cash from operating activities refers to the money it takes in and takes out as a result of its regular business operations. PRLD generated -$21.69M of Cash from Operating Activities during its recently reported quarter.
What was PRLD's latest reported Net Change in Cash?
An increase or decrease in cash and cash equivalent balances within a specified period is considered the net change in cash in a cash flow statement. Furthermore, it takes into account cash changes as a result of investments, financing, and operating activities. PRLD reported a -$13.50M Net Change in Cash in the most recent quarter.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph